M/s. KamlaAmrut Pharmaceutical LLP, Survey No.: 53,56,57, Nr. KamlaAmrut Industrial Park, Indrad, Ta.: Kadi, Dist.: Mehsana, Gujarat - 382715, Susmita Roy, B pharm, M ...

Like other medications for the treatment of (ED), Cialis — and its generic version, tadalafil — can cause adverse effects at first. Fortunately, most tadalafil side effects are mild and ...

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active ...

The growth prospects of the Indian economy are likely to improve in the forthcoming quarters and the Financial Year 2026 is expected to be better than FY25, driven by fiscal tailwinds, private ...

Cipla has been given a new recommendation by brokerage Axis Securities, indicating a potential upside of 15.24%. The target price is Rs 1735.0, while the stock was priced at Rs 1489.0 at the time of ...

Analysts have given recommendations for companies including Devyani International Ltd., Cipla Ltd., Oberoi Realty Ltd., Bank Of Baroda, and more. As per the stock calls shared with NDTV Profit, some ...

Cipla's stock is trading at Rs 1470.80, down by 0.34% today. The 5-year returns highlight a strong performance with a total of 216.19%. The last trading session saw Cipla close at Rs 1475.75, with a ...

Shares of Cipla gained nearly 2 per cent on Monday, following the United States Food and Drug Administration (USFDA) classifying its Goa facility as “Voluntary Action Indicated” (VAI ...

Drugmaker Cipla on Monday said that it has signed a perpetual license agreement with Switzerland-based Novartis Pharma AG to manufacture and market Galvus and Galvus combination brands which are used ...

Novartis and Cipla signed a perpetual licence agreement for the diabetes drug Galvus. Credit: Novartis AG. India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with ...